Watson Scores Win In J&J Patent Spat Over Concerta

Law360, New York (March 31, 2009, 12:00 AM EDT) -- Handing a win to Watson Pharmaceuticals Inc., a federal court has ruled that a Watson subsidiary's generic version of attention deficient disorder treatment Concerta would not infringe a patent asserted by two Johnson & Johnson units.

In a 105-page decision handed down Monday by Judge Joseph Farnan of the U.S. District Court for the District of Delaware, the court ruled that the patent-at-issue was not valid or infringed by Watson's Andrx Corp.'s filing of an abbreviated new drug application.

Alza Corp. and McNeil-PPC Inc., two J&J...
To view the full article, register now.